COMP <GO>
CHE vs HIMS // DIVIDEND YIELD & FCF PAYOUT SAFETY
Chemed Corp (NYSE) VS. Hims & Hers Health Inc. (NYSE) • 15-METRIC TALLY: CHE 10
— HIMS 3
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: CHE
LAST: $541.92 (+1.61%) • MKT CAP: $7.08B
dividend-safety
0.45%
LAST: $29.67 (+1.19%) • MKT CAP: $6.92B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHE VS. HIMS)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHE | HIMS | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 32.50% | 73.80% | -41.30 | HIMS | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 23.40% | 8.40% | +15.00 | CHE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.5x | 37.7x | -19.20 | CHE | /valuation <GO> |
| Free Cash Flow Yield | 4.60% | 2.81% | +1.79 | CHE | /fcf-yield <GO> |
| Operating Margin | 13.40% | 4.50% | +8.90 | CHE | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 5.50% | -5.50 | HIMS | /net-margins <GO> |
| Revenue Growth (YoY) | 65.30% | 59.00% | +6.30 | CHE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.45% | 0.00% | +0.45 | CHE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 12.68 | 3.95 | +8.73 | CHE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 8/9 | -1.00 | HIMS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.9 | 53.1 | +11.80 | CHE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.08 | 1.05 | +0.03 | CHE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 45.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.08B | $6.92B | $160.5M | CHE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHE REV | HIMS REV | CHE GROSS % | HIMS GROSS % | CHE FCF | HIMS FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.53B | $2.35B | 32.5% | 73.8% | $325.5M | $194.4M |
| FY 2024 | $1.53B | $1.48B | — | 79.5% | $368.0M | $184.6M |
| FY 2023 | $1.32B | $872.0M | — | — | $271.1M | $34.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHE // BETA 1.08
HIMS // BETA 1.05